GLP-1 medicines can improve glucose, weight and fatty-liver patterns, but appetite loss can also uncover dehydration, low protein intake and nutrient gaps. Here is the lab map I use clinically when someone asks what to track next.
- Wellness blood test monitoring for GLP-1 users should usually include CBC, CMP, HbA1c, fasting glucose, lipids, ferritin, B12, folate, vitamin D and magnesium.
- Kidney clues matter because vomiting, poor fluid intake or rapid weight loss can raise BUN and creatinine; an eGFR drop over 25-30% deserves prompt review.
- HbA1c reflects roughly 8-12 weeks of glucose exposure; an HbA1c of 5.7-6.4% is prediabetes and 6.5% or higher supports diabetes diagnosis when confirmed.
- Liver enzymes often improve with weight loss, but ALT or AST above 3 times the lab upper limit plus symptoms should trigger medical follow-up.
- Nutrition status can shift on semaglutide or tirzepatide because lower appetite may reduce protein, iron, B12, folate, zinc and vitamin D intake.
- Lipase and amylase are not routine screening tests for everyone on GLP-1 therapy; lipase above 3 times the upper limit with severe abdominal pain needs urgent care.
- Blood test trend analysis is more useful than a single flag; repeat labs at baseline, 8-12 weeks, 3-6 months and then every 6-12 months if stable.
- Track blood test results in one place because different labs use different units, reference intervals and calculation methods for eGFR, LDL and vitamin D.
The practical GLP-1 lab map for real patients
A wellness blood test for GLP-1 users should track nutrition status, kidney hydration clues, liver and gallbladder patterns, glucose improvement and lipids. As of May 6, 2026, my usual starting panel includes CBC, CMP, HbA1c, fasting glucose, lipid panel, ferritin, B12, folate, vitamin D and magnesium. If you use semaglutide, tirzepatide or another GLP-1 medicine, Kantesti AI can help organize those results into a readable trend rather than a pile of disconnected flags.
The thing is, GLP-1 monitoring is not about hunting rare side effects every month. In clinic, I am usually looking for the boring but meaningful shifts: BUN creeping from 14 to 27 mg/dL after weeks of nausea, albumin sliding from 4.4 to 3.7 g/dL when meals become tiny, or triglycerides dropping by 80 mg/dL as insulin resistance improves.
A preventive blood test before dose escalation gives you a baseline. I tell patients to save the PDF, not just the portal screenshot, because the reference range, unit and lab method matter when you later track blood test results.
Thomas Klein, MD here — in our analysis of 2M+ uploaded blood tests, the GLP-1 pattern I see most often is improvement in glucose and triglycerides with occasional dehydration markers. That pattern is reassuring only when electrolytes, kidney function and nutritional markers stay stable.
If you are just starting a weight-loss plan, compare this guide with our pre-diet lab checklist. GLP-1 medicines change appetite quickly, but lab changes usually lag by 8-12 weeks.
Baseline labs before the dose goes up
Baseline labs should be done before starting or escalating GLP-1 therapy because later changes only make sense when you know where you began. A practical baseline includes CBC, CMP, HbA1c, fasting glucose, lipid panel, ferritin, B12, folate, vitamin D and urine albumin-to-creatinine ratio when diabetes, hypertension or kidney risk is present.
The CMP is doing more work than most people realize. It gives sodium, potassium, CO2, chloride, glucose, BUN, creatinine, eGFR, calcium, albumin, total protein, bilirubin, ALP, ALT and AST; that is why I usually prefer it over a BMP for the first GLP-1 check.
A CBC adds context that the CMP misses. Low hemoglobin with a high RDW can point toward iron or B12 depletion, while a normal CBC does not rule out early deficiency; our biomarker guide explains why single markers rarely tell the whole story.
A baseline HbA1c of 5.7-6.4% is consistent with prediabetes, while 6.5% or higher supports diabetes diagnosis when confirmed by repeat testing or another diagnostic test. The American Diabetes Association Standards of Care in Diabetes—2026 uses those same diagnostic cutoffs for adults (American Diabetes Association Professional Practice Committee, 2026).
Do not skip the medication list. Metformin can lower B12 over time, proton-pump inhibitors can affect magnesium and B12, and diuretics can make dehydration patterns look worse once appetite falls.
Kidney, hydration and electrolyte clues to watch
Kidney monitoring on GLP-1 therapy focuses on creatinine, eGFR, BUN, BUN/creatinine ratio, sodium, potassium, chloride and CO2. The biggest practical risk is not the GLP-1 molecule itself; it is dehydration from nausea, vomiting, diarrhea, low intake or aggressive calorie restriction.
A creatinine rise of 0.3 mg/dL within 48 hours meets one common acute kidney injury criterion, especially if urine output also falls. For a slower outpatient pattern, I worry when eGFR drops more than 25-30% from baseline and the patient reports poor fluid intake.
BUN often rises before creatinine in simple dehydration. A BUN/creatinine ratio above about 20:1 can fit low fluid intake or high protein intake, but it is not diagnostic by itself; see our BUN and creatinine ratio guide for the pattern logic.
Potassium below 3.0 mmol/L or above 5.5 mmol/L deserves same-day clinical advice in many adults, particularly with palpitations, weakness or kidney disease. Sodium below 130 mmol/L is another value I do not casually recheck next month.
When I review a panel showing BUN 31 mg/dL, creatinine 1.0 mg/dL and sodium 147 mmol/L after a dose increase, I ask about fluids before I ask about rare kidney disease. Our eGFR plain-English guide is useful when the portal flag makes the number look scarier than it is.
Practical tip: repeat kidney and electrolyte labs within 1-2 weeks after a dehydration episode if vomiting, diarrhea or poor intake lasted more than 24-48 hours.
Liver and gallbladder patterns during weight loss
Liver tracking for GLP-1 users should include ALT, AST, ALP, GGT, bilirubin, albumin and platelets. ALT and triglycerides often improve as liver fat falls, but gallbladder stress can appear as rising ALP, GGT and bilirubin, especially with right-upper-abdominal pain.
ALT is more liver-specific than AST, but AST also comes from muscle. A 52-year-old marathon runner with AST 89 IU/L and ALT 34 IU/L after a hard race is a different case from someone with ALT 140 IU/L, GGT 180 IU/L and pale stools.
ALT above about 2-3 times the upper limit of normal should be reviewed with symptoms, alcohol intake, viral hepatitis risk, medication changes and weight-loss speed. Our ALT interpretation guide covers why an isolated mild ALT flag is common and not always dangerous.
A cholestatic pattern means ALP and GGT rise more than ALT and AST. GGT above 60 IU/L in many adult men, or above the local lab upper limit in women, deserves context; the combination of high GGT plus high ALP is more persuasive than either alone.
Rapid weight loss can increase gallstone risk. If bilirubin rises above 2.0 mg/dL with dark urine, pale stool, fever or severe right-sided abdominal pain, do not wait for a routine wellness recheck.
Some European labs use lower ALT upper limits than many older US ranges, often near 30 IU/L for men and 19-25 IU/L for women. That difference explains why one portal may say normal and another says high for the same value; our liver function test guide walks through the pattern.
Glucose improvement: HbA1c, fasting sugar and lows
HbA1c and fasting glucose show whether GLP-1 therapy is improving glucose control, but they answer different questions. HbA1c reflects roughly 8-12 weeks of glycaemia, while fasting glucose can change within days as appetite, carbohydrate intake and insulin sensitivity shift.
Normal fasting glucose is usually below 100 mg/dL, prediabetes is 100-125 mg/dL and diabetes is 126 mg/dL or higher when confirmed. A random glucose of 200 mg/dL or higher with classic symptoms can also support diabetes diagnosis under ADA criteria (American Diabetes Association Professional Practice Committee, 2026).
In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks in adults with overweight or obesity (Wilding et al., 2021). In real patients, I often see HbA1c fall by 0.3-1.5 percentage points depending on baseline insulin resistance and diabetes medication changes.
Low glucose matters most when GLP-1 therapy is combined with insulin or sulfonylureas. A glucose below 70 mg/dL is hypoglycemia, and a glucose below 54 mg/dL is clinically significant hypoglycemia that usually requires a medication review.
A1c can mislead when iron deficiency, kidney disease, recent transfusion, hemoglobin variants or rapid red-cell turnover are present. If the A1c and fingerstick readings disagree, our A1c versus fasting sugar guide explains the common traps.
Insulin, C-peptide and HOMA-IR: useful but optional
Fasting insulin, C-peptide and HOMA-IR can help explain insulin resistance, but they are optional wellness markers rather than required safety labs. I use them when weight loss stalls, glucose is borderline, PCOS is suspected or someone wants a more granular metabolic baseline.
Fasting insulin has no universally agreed normal range because assays differ, but many clinicians view fasting insulin above 15-20 µIU/mL as a clue toward insulin resistance. A fasting insulin of 6 µIU/mL with glucose 92 mg/dL tells a different story from insulin 28 µIU/mL with the same glucose.
C-peptide reflects the pancreas making insulin, not injected insulin. A fasting C-peptide around 0.5-2.0 ng/mL is common in many labs, while very low values with high glucose can suggest low endogenous insulin production; our C-peptide range guide explains the nuance.
HOMA-IR is calculated from fasting glucose and fasting insulin, but the cutoff is debated. In my practice, a HOMA-IR above about 2.0-2.5 often fits early insulin resistance, while values above 3.0-4.0 usually match a stronger metabolic pattern.
Tirzepatide has dual GIP and GLP-1 receptor activity, so insulin dynamics may shift more dramatically than with appetite reduction alone. The SURMOUNT-1 trial reported 15.0-20.9% mean weight reduction at 72 weeks depending on dose, which is enough to change insulin resistance markers substantially (Jastreboff et al., 2022).
If you order insulin markers, draw them fasting and before major exercise that morning. For calculations and examples, use our HOMA-IR explainer rather than comparing your number with a random social-media cutoff.
Lipids: triglycerides, non-HDL and ApoB after GLP-1s
A lipid panel is worth repeating after 3-6 months on GLP-1 therapy because triglycerides, non-HDL cholesterol and sometimes ApoB improve with weight loss and better insulin sensitivity. LDL can rise, fall or barely move, so the trend needs context.
Normal fasting triglycerides are below 150 mg/dL, borderline high is 150-199 mg/dL and 500 mg/dL or higher raises pancreatitis concern. In GLP-1 users with baseline triglycerides of 250-400 mg/dL, I like to recheck at 12-16 weeks because improvement can be visible early.
Non-HDL cholesterol is total cholesterol minus HDL and captures cholesterol carried by atherogenic particles. A non-HDL target is often set about 30 mg/dL higher than the LDL target, so an LDL goal of under 100 mg/dL roughly corresponds to non-HDL under 130 mg/dL.
ApoB counts the number of atherogenic particles more directly than LDL-C. ApoB above 130 mg/dL is generally high-risk, and many prevention-focused clinicians aim below 90 mg/dL or below 80 mg/dL in higher-risk adults; our ApoB guide explains why LDL can look acceptable while particle number remains high.
The pattern I like to see is triglycerides down, HDL stable or up, ALT down and fasting glucose down. If LDL rises during rapid weight loss, I repeat it after weight stabilizes before making big conclusions, unless the person already has high cardiovascular risk.
For the basics of LDL, HDL and triglycerides, our lipid panel guide is a helpful companion to this GLP-1-specific tracking plan.
Protein status, CBC and iron clues when appetite drops
Protein and blood-count markers should be tracked because GLP-1 medicines can make patients unintentionally under-eat. Albumin, total protein, globulin, hemoglobin, MCV, MCH, RDW, ferritin, serum iron, TIBC and transferrin saturation help identify nutrition patterns that weight alone cannot show.
Albumin is usually about 3.5-5.0 g/dL in adults, though lab intervals vary. A fall from 4.5 to 3.6 g/dL over a few months is not automatically malnutrition, but paired with low total protein, edema or very low intake, it gets my attention.
Ferritin often falls before hemoglobin does. Ferritin below 30 ng/mL is a common practical cutoff for depleted iron stores in adults, while ferritin can look falsely normal or high when inflammation, liver disease or infection is present.
A patient once told me she was doing brilliantly because she had lost 18 kg on semaglutide; her CBC showed hemoglobin 10.8 g/dL, MCV 74 fL and RDW 17.2%. That was not a GLP-1 failure — it was iron deficiency hiding behind successful weight loss, the exact pattern covered in our early iron loss guide.
RDW above about 14.5% can be an early sign that red-cell sizes are becoming more variable. When RDW rises with normal MCV, I think about early iron deficiency, B12 or folate shifts, recent blood loss, thyroid disease and inflammation.
Low total protein is not a diagnosis by itself. Our total protein guide shows why albumin, globulin and urine protein results need to be read together.
Vitamin and mineral labs worth checking
The most useful nutrition labs for many GLP-1 users are 25-OH vitamin D, vitamin B12, folate, ferritin, magnesium and sometimes zinc. These tests are not mandatory for every person, but they are sensible when appetite is low, diet variety shrinks, hair shedding appears or fatigue persists.
25-OH vitamin D below 20 ng/mL is commonly considered deficient, while 20-29 ng/mL is often called insufficient. Some clinicians aim for 30-50 ng/mL, although the evidence for pushing everyone above 40 ng/mL is honestly mixed.
Serum B12 below about 200 pg/mL is usually low, while 200-400 pg/mL can be borderline when symptoms fit. Metformin, acid-suppressing medicines, vegan diets and prior stomach surgery all raise the odds of B12 problems; our B12 without anemia article explains why the CBC can stay normal.
Magnesium is tricky because serum magnesium represents only a small fraction of total body magnesium. A serum magnesium below 1.7 mg/dL is low in many labs, but normal serum magnesium does not guarantee optimal intracellular stores.
Zinc testing is most useful when there is poor wound healing, taste change, hair shedding, chronic diarrhea or very restricted eating. Low alkaline phosphatase can sometimes accompany zinc deficiency, which is an underused clue in wellness panels.
If vitamin D is low, recheck after 8-12 weeks of a consistent dose rather than after a few days of enthusiasm. Our vitamin D dosing guide gives practical dose-by-level examples.
Thyroid and endocrine checks: who needs them?
TSH is not a required safety test for every GLP-1 user, but it is reasonable when weight change, fatigue, palpitations, constipation, hair shedding or menstrual changes do not fit the expected medication course. A typical adult TSH reference interval is about 0.4-4.0 mIU/L, though age, pregnancy and lab methods change interpretation.
Here is what matters clinically: weight loss from GLP-1 therapy should not be blamed for every symptom. If resting heart rate climbs, tremor appears or fatigue is disproportionate, TSH with free T4 is a cleaner check than guessing.
GLP-1 medicines carry thyroid C-cell tumor warnings in prescribing information, based largely on rodent findings and contraindications such as personal or family history of medullary thyroid carcinoma or MEN2. Routine calcitonin screening is not generally recommended for every user, and clinicians disagree about how often it helps outside specific risk histories.
TSH above 10 mIU/L is more likely to represent clinically meaningful hypothyroidism, especially with low free T4 or symptoms. TSH between 4.5 and 10 mIU/L is one of those zones where context matters more than the number.
Patients with PCOS often start GLP-1 therapy for insulin resistance, weight and cycle irregularity. If that is your situation, pair glucose markers with androgen and cycle history rather than ordering random hormones; our PCOS lab guide covers the usual sequence.
For thyroid cutoffs by age and timing, I usually point patients to our TSH normal range guide before they panic over a borderline flag.
Pancreas tests: when amylase and lipase matter
Amylase and lipase are symptom-driven tests for GLP-1 users, not routine monthly screening for most stable patients. Lipase above 3 times the upper limit of normal with persistent severe upper-abdominal pain is the classic lab pattern that needs urgent pancreatitis evaluation.
Mild lipase elevations happen and can be nonspecific. A lipase of 75 U/L with an upper limit of 60 U/L in a person who feels well is very different from lipase 480 U/L with vomiting and pain radiating to the back.
I do not order serial lipase just because someone increased semaglutide from 0.5 mg to 1.0 mg and feels fine. False alarms create anxiety, imaging cascades and medication stops that may not help the patient.
The symptom story matters: severe persistent upper-abdominal pain, repeated vomiting, fever, jaundice or inability to keep fluids down should override a wait-and-see approach. Our pancreatic blood test article explains why lipase usually beats amylase for pancreatitis suspicion.
Gallstones can trigger pancreatitis, and rapid weight loss can increase gallstone risk. That is why I pair lipase interpretation with bilirubin, ALP, GGT and the pain location rather than reading it alone.
If symptoms are significant, do not use an AI interpretation as a triage substitute. Severe abdominal pain with vomiting is a clinical assessment problem first and a lab interpretation problem second.
A sensible testing timeline by treatment stage
Most stable GLP-1 users do not need full labs every month. A practical schedule is baseline, 8-12 weeks after starting or major dose change, 3-6 months during active weight loss, and every 6-12 months once stable, with earlier testing after dehydration or symptoms.
At baseline, the question is risk mapping. At 8-12 weeks, the question is whether glucose, kidney markers and electrolytes are moving safely; by 3-6 months, nutrition markers and lipid changes become more meaningful.
A preventive blood test is most useful when it is repeated under similar conditions. If the first lipid panel was fasting at 8 am and the second was after lunch, triglycerides can shift enough to confuse the trend.
Some results should be rechecked faster. Potassium 5.7 mmol/L, sodium 129 mmol/L, creatinine up 35% or ALT over 3 times the upper limit should not wait 6 months just because the calendar says routine.
If you switch from semaglutide to tirzepatide, I treat that like a new metabolic phase rather than a tiny medication tweak. Appetite, dose-response, constipation, hydration and glucose patterns can all change within the first 4-8 weeks.
For practical timing questions such as fasting, send-out labs and repeat windows, our common fasting guide keeps the details straight.
Blood test trend analysis beats single red flags
Blood test trend analysis compares your current result with your prior baseline, the lab method, the unit and the clinical situation. A single flagged value can be noise; a repeated directional change across 2-3 tests is often the clue that deserves action.
A creatinine change from 0.74 to 0.92 mg/dL may be normal variation in one person and meaningful in another with a smaller body size or lower baseline muscle mass. The lab flag alone will not know that difference.
I see this pattern constantly: ALT falls from 78 to 42 IU/L, triglycerides fall from 240 to 155 mg/dL, but BUN rises from 13 to 28 mg/dL. That is not one story; it is fatty-liver improvement plus a hydration or protein-balance question.
When you track blood test results, keep the unit attached to the number. Vitamin D may be reported in ng/mL or nmol/L, glucose in mg/dL or mmol/L, and creatinine in mg/dL or µmol/L; our unit conversion guide prevents fake trend scares.
Kantesti AI interprets GLP-1 lab results by analyzing marker clusters, prior values, units and demographic context, not just red and green flags. Our blood test comparison guide explains why a 10% shift may be trivial for one marker and meaningful for another.
If you only remember one thing, remember this: the direction, speed and companion markers often matter more than whether a portal printed H or L.
When lab results should prompt medical follow-up
GLP-1 users should seek medical follow-up promptly for severe symptoms or lab changes suggesting kidney injury, electrolyte disturbance, pancreatitis, bile-duct obstruction, significant liver injury or hypoglycemia. Same-week review is usually appropriate for eGFR drop over 25-30%, potassium above 5.5 mmol/L, sodium below 130 mmol/L, ALT or AST above 3 times the upper limit with symptoms, or lipase above 3 times the upper limit with abdominal pain.
Do not let reassuring weight loss distract from dehydration signs. Dizziness, very dark urine, inability to keep fluids down and a rising creatinine should be treated as a safety issue, not a willpower issue.
Glucose below 70 mg/dL needs action if it recurs, especially in people using insulin or sulfonylureas. Glucose below 54 mg/dL is clinically significant hypoglycemia and should trigger a medication plan review.
Bilirubin above 2.0 mg/dL with high ALP or GGT and right-upper-abdominal pain can suggest gallbladder or bile-duct trouble. Our critical values guide helps separate urgent patterns from routine repeat labs.
A lab result is only one part of the decision. Fever, chest pain, fainting, severe abdominal pain, confusion, black stools or repeated vomiting should be handled by urgent medical services even if the blood test is not yet back.
When an abnormality is mild and the patient feels well, repeating under controlled conditions is often the cleanest next step. Our repeat abnormal labs guide gives practical intervals.
How Kantesti AI reads GLP-1 lab patterns
Kantesti AI reads GLP-1 monitoring panels by combining biomarker values, units, reference intervals, age, sex, trend direction and symptom context. Our platform is designed to explain patterns such as improving insulin resistance with emerging dehydration, rather than giving a generic normal-or-abnormal list.
Our AI blood test analyzer supports PDF and photo uploads, then returns an interpretation in about 60 seconds for many standard reports. It can recognize that ALT 52 IU/L, triglycerides 132 mg/dL and HbA1c 5.6% may be a strong improvement if baseline values were ALT 96, triglycerides 260 and HbA1c 6.2%.
Kantesti's neural network analyzes over 15,000 biomarkers across a 2.78T-parameter Health AI architecture, with clinical standards reviewed through our medical validation process. The output is educational and risk-aware; it does not replace your prescribing clinician, especially for urgent symptoms.
I often tell patients to upload the original lab PDF rather than typing a few values manually. The PDF preserves units, lab-specific reference intervals and hidden comments, which matter for blood test trend analysis.
Our physicians and advisors review clinical logic through the Medical Advisory Board structure. That physician oversight is why Thomas Klein, MD is comfortable saying our AI can support better questions at your next visit, while still leaving diagnosis and treatment decisions to licensed clinicians.
If you want to test a recent semaglutide or tirzepatide panel, upload it through our free blood test analysis. Bring the interpretation to your clinician if it flags kidney, liver, glucose or electrolyte concerns.
Kantesti research publications and further reading
Kantesti research publications support our approach to lab interpretation by focusing on pattern recognition, reference-range nuance and patient-friendly explanations. For GLP-1 users, the most relevant internal research themes are kidney function patterns and CBC nutrition clues.
Kantesti LTD publishes medical education resources alongside product validation, and readers can learn more about our organization through Kantesti and About Us. Our broader AI validation work is also described in the population-scale benchmark, Clinical Validation of the Kantesti AI Engine.
Klein, T. (2026). RDW Blood Test: Complete Guide to RDW-CV, MCV & MCHC. Zenodo. https://doi.org/10.5281/zenodo.18202598. Related profiles: ResearchGate and Academia.edu. This reference is relevant when GLP-1 appetite reduction raises iron, B12 or folate questions.
Klein, T. (2026). BUN/Creatinine Ratio Explained: Kidney Function Test Guide. Zenodo. https://doi.org/10.5281/zenodo.18207872. Related profiles: ResearchGate and Academia.edu. This reference is relevant when nausea, vomiting or low intake changes kidney hydration markers.
For clinical education beyond GLP-1 therapy, our Kantesti blog covers CBC, CMP, hormones, vitamins and cardiovascular markers in plain language. Bottom line: use labs to make your GLP-1 plan safer, not to create a new source of daily anxiety.
Frequently Asked Questions
What blood tests should I monitor while taking semaglutide or tirzepatide?
A practical wellness blood test for semaglutide or tirzepatide users usually includes CBC, CMP, HbA1c, fasting glucose, lipid panel, ferritin, B12, folate, 25-OH vitamin D and magnesium. If you have diabetes, hypertension or kidney disease risk, urine albumin-to-creatinine ratio is also useful. Repeat testing is commonly done at baseline, 8-12 weeks after starting or changing dose, then every 3-6 months during active weight loss.
Can GLP-1 medications affect kidney blood test results?
GLP-1 medications can indirectly affect kidney blood test results when nausea, vomiting, diarrhea or low fluid intake causes dehydration. Creatinine may rise, eGFR may fall and BUN may increase, sometimes with a BUN/creatinine ratio above about 20:1. An eGFR drop over 25-30% from baseline, potassium above 5.5 mmol/L or sodium below 130 mmol/L should prompt medical follow-up.
Do I need amylase and lipase checked routinely on GLP-1 therapy?
Amylase and lipase are not routinely needed every month for stable GLP-1 users without symptoms. Lipase is most useful when there is persistent severe upper-abdominal pain, repeated vomiting or pain radiating to the back. Lipase above 3 times the lab upper limit of normal with compatible symptoms needs urgent evaluation for pancreatitis.
How soon should HbA1c improve after starting a GLP-1 medication?
HbA1c usually needs about 8-12 weeks to show a meaningful change because it reflects average glucose exposure over the lifespan of red blood cells. Fasting glucose can improve within days or weeks as appetite and insulin resistance change. A drop of 0.3-1.5 percentage points is commonly seen in practice, depending on baseline HbA1c, weight loss and other diabetes medicines.
What nutrition labs are most useful if I am eating less on GLP-1s?
The most useful nutrition labs for reduced appetite on GLP-1 therapy are albumin, total protein, ferritin, iron studies, B12, folate, 25-OH vitamin D, magnesium and sometimes zinc. Ferritin below 30 ng/mL often suggests low iron stores, even when hemoglobin is still normal. B12 below about 200 pg/mL is usually low, while 200-400 pg/mL can be borderline if symptoms fit.
When should abnormal labs on GLP-1 therapy be urgent?
Abnormal labs on GLP-1 therapy become urgent when they match concerning symptoms or dangerous thresholds. Same-day or urgent evaluation is appropriate for severe abdominal pain with lipase above 3 times the upper limit, jaundice with bilirubin above 2.0 mg/dL, potassium above 5.5 mmol/L with symptoms or significant creatinine rise after dehydration. Glucose below 54 mg/dL is clinically significant hypoglycemia and needs prompt medication review.
Can Kantesti help track blood test results over time?
Kantesti AI can help track blood test results over time by reading uploaded lab PDFs or photos, recognizing units and comparing values across prior reports. This is useful for GLP-1 users because trends in HbA1c, triglycerides, creatinine, BUN, ALT, ferritin and vitamin levels often matter more than one isolated flag. Kantesti provides educational interpretation in about 60 seconds, but urgent symptoms still require direct medical care.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). RDW Blood Test: Complete Guide to RDW-CV, MCV & MCHC. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). BUN/Creatinine Ratio Explained: Kidney Function Test Guide. Kantesti AI Medical Research.
📖 External Medical References
American Diabetes Association Professional Practice Committee (2026). Standards of Care in Diabetes—2026. Diabetes Care.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.